Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 334

1.

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK.

Lancet HIV. 2019 Oct 11. pii: S2352-3018(19)30338-8. doi: 10.1016/S2352-3018(19)30338-8. [Epub ahead of print]

PMID:
31611038
2.

Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.

Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, Rae Z, Hernandez JM, Davis JL, Martin SP, Kleiner DE, Hewitt SM, Ylaya K, Wood BJ, Greten TF, Wang XW.

Cancer Cell. 2019 Oct 14;36(4):418-430.e6. doi: 10.1016/j.ccell.2019.08.007. Epub 2019 Oct 3.

3.

Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.

Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, Cummings O, Yeh M, Gill R, Chalasani N, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Terrault N, Kowdley K, Loomba R, Belt P, Tonascia J, Lavine JE, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network.

JAMA Netw Open. 2019 Oct 2;2(10):e1912565. doi: 10.1001/jamanetworkopen.2019.12565.

PMID:
31584681
4.

Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials.

Pai RK, Kleiner DE, Hart J, Adeyi OA, Clouston AD, Behling CA, Jain D, Kakar S, Brahmania M, Burgart L, Batts KP, Valasek MA, Torbenson MS, Guindi M, Wang HL, Ajmera V, Adams LA, Parker CE, Feagan BG, Loomba R, Jairath V.

Aliment Pharmacol Ther. 2019 Oct 3. doi: 10.1111/apt.15503. [Epub ahead of print]

PMID:
31583739
5.

No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication.

Bozzi G, Simonetti FR, Watters SA, Anderson EM, Gouzoulis M, Kearney MF, Rote P, Lange C, Shao W, Gorelick R, Fullmer B, Kumar S, Wank S, Hewitt S, Kleiner DE, Hattori J, Bale MJ, Hill S, Bell J, Rehm C, Grossman Z, Yarchoan R, Uldrick T, Maldarelli F.

Sci Adv. 2019 Sep 25;5(9):eaav2045. doi: 10.1126/sciadv.aav2045. eCollection 2019 Sep.

6.

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.

Vos MB, Dimick-Santos L, Mehta R, Omokaro SO, Taminiau J, Schabel E, Kleiner DE, Szitanyi P, Socha P, Schwimmer JB, Noviello S, Silberg DG, Torstenson R, Miller V, Lavine JE.

Gastroenterology. 2019 Sep 11. pii: S0016-5085(19)41312-7. doi: 10.1053/j.gastro.2019.08.048. [Epub ahead of print] No abstract available.

PMID:
31520612
7.

Rely to HEP-19-1327.

Sterling RK, King WC, Kleiner DE.

Hepatology. 2019 Aug 21. doi: 10.1002/hep.30901. [Epub ahead of print]

PMID:
31432525
8.

Exploring the Link Between Platelet Numbers and Vascular Homeostasis Across Early and Late Stages of Fibrosis in Hepatitis C.

Ali RO, Moon MS, Townsend EC, Hill K, Zhang GY, Bradshaw A, Guan H, Hamilton D, Kleiner DE, Auh S, Koh C, Heller T.

Dig Dis Sci. 2019 Aug 12. doi: 10.1007/s10620-019-05760-x. [Epub ahead of print]

PMID:
31407130
9.

Bacterial Translocation and Host Immune Activation in Chronic Hepatitis C Infection.

Moon MS, Quinn G, Townsend EC, Ali RO, Zhang GY, Bradshaw A, Hill K, Guan H, Hamilton D, Kleiner DE, Koh C, Heller T.

Open Forum Infect Dis. 2019 Jul 1;6(7). pii: ofz255. doi: 10.1093/ofid/ofz255.

10.

Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV.

Balmaceda JB, Aepfelbacher J, Belliveau O, Chaudhury CS, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Kleiner DE, Hadigan C.

Antivir Ther. 2019 Jul 30. doi: 10.3851/IMP3327. [Epub ahead of print]

PMID:
31359874
11.

A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer.

Floudas CS, Brar G, Mabry-Hrones D, Duffy AG, Wood B, Levy E, Krishnasamy V, Fioravanti S, Bonilla CM, Walker M, Morelli MP, Kleiner DE, Steinberg SM, Figg WD, Greten TF, Xie C.

Clin Colorectal Cancer. 2019 Jul 2. pii: S1533-0028(19)30243-9. doi: 10.1016/j.clcc.2019.06.004. [Epub ahead of print]

12.

Portal Pressure in Noncirrhotic Portal Hypertension: To Measure or Not to Measure.

Da BL, Surana P, Kapuria D, Vittal A, Levy E, Kleiner DE, Koh C, Heller T.

Hepatology. 2019 Jul 18. doi: 10.1002/hep.30862. [Epub ahead of print] No abstract available.

PMID:
31318454
13.

Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults.

Sterling RK, King WC, Wahed AS, Kleiner DE, Khalili M, Sulkowski M, Chung RT, Jain MK, Lisker-Melman M, Wong DK, Ghany MG; HIV-HBV Cohort Study of the Hepatitis B Research Network.

Hepatology. 2019 Jun 20. doi: 10.1002/hep.30825. [Epub ahead of print]

PMID:
31220357
14.

Vibration Controlled Transient Elastography (Fibroscan®) in sickle cell liver disease - could we strike while the liver is hard?

Ben Yakov G, Sharma D, Alao H, Surana P, Kapuria D, Etzion O, Hsieh MM, Tisdale JF, Fitzhugh CD, Kleiner DE, Levy EB, Chang R, Rivera E, Huang A, Koh C, Heller T.

Br J Haematol. 2019 Oct;187(1):117-123. doi: 10.1111/bjh.16047. Epub 2019 Jun 19.

PMID:
31218662
15.

Antimicrobials and Antiepileptics Are the Leading Causes of Idiosyncratic Drug-induced Liver Injury in American Children.

DiPaola F, Molleston JP, Gu J, Cirulli ET, Chalasani N, Barnhart H, Kleiner DE, Hoofnagle JH, Fontana RJ; US Drug Induced Liver Injury Network.

J Pediatr Gastroenterol Nutr. 2019 Aug;69(2):152-159. doi: 10.1097/MPG.0000000000002383.

PMID:
31169665
16.

Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance.

Ferré EMN, Break TJ, Burbelo PD, Allgäuer M, Kleiner DE, Jin D, Xu Z, Folio LR, Mollura DJ, Swamydas M, Gu W, Hunsberger S, Lee CR, Bondici A, Hoffman KW, Lim JK, Dobbs K, Niemela JE, Fleisher TA, Hsu AP, Snow LN, Darnell DN, Ojaimi S, Cooper MA, Bozzola M, Kleiner GI, Martinez JC, Deterding RR, Kuhns DB, Heller T, Winer KK, Rajan A, Holland SM, Notarangelo LD, Fennelly KP, Olivier KN, Lionakis MS.

Sci Transl Med. 2019 Jun 5;11(495). pii: eaav5597. doi: 10.1126/scitranslmed.aav5597.

PMID:
31167928
17.

Longitudinal effects of Nucleos(t)ide analogue therapy in chronic hepatitis B patients and the utility of non-invasive fibrosis markers during treatment: A single-center experience for up to 17 years.

Surana P, Kapuria D, Broadwell C, Wright EC, Takyar V, Kleiner DE, Ghany MG, Ben-Yakov G, Heller T, Liang TJ, Koh C.

Antiviral Res. 2019 Aug;168:61-67. doi: 10.1016/j.antiviral.2019.05.007. Epub 2019 May 21.

PMID:
31125632
18.

Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum.

Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, Ratziu V, Sanyal AJ, Loomba R, Jeannin Megnien S, Torstenson R, Miller V; Liver Forum Case Definitions Working Group.

Hepatology. 2019 Apr 29. doi: 10.1002/hep.30672. [Epub ahead of print]

PMID:
31034092
19.

Hepatitis B Surface Antigen Activates Unfolded Protein Response in Forming Ground Glass Hepatocytes of Chronic Hepatitis B.

Li Y, Xia Y, Cheng X, Kleiner DE, Hewitt SM, Sproch J, Li T, Zhuang H, Liang TJ.

Viruses. 2019 Apr 25;11(4). pii: E386. doi: 10.3390/v11040386.

20.

Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.

Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, Pelayo E, Beach M, Gulley JL, Madan RA, Feliciano J, Grisius M, Long L, Powers A, Kleiner DE, Cappelli L, Alevizos I.

Oncologist. 2019 Sep;24(9):1259-1269. doi: 10.1634/theoncologist.2018-0823. Epub 2019 Apr 17.

PMID:
30996010
21.

Hepatic Manifestations of Cystic Fibrosis.

Sakiani S, Kleiner DE, Heller T, Koh C.

Clin Liver Dis. 2019 May;23(2):263-277. doi: 10.1016/j.cld.2018.12.008. Epub 2019 Feb 21. Review.

PMID:
30947876
22.

Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors.

Stolz A, Navarro V, Hayashi PH, Fontana RJ, Barnhart HX, Gu J, Chalasani NP, Vega MM, Bonkovsky HL, Seeff LB, Serrano J, Avula B, Khan IA, Cirulli ET, Kleiner DE, Hoofnagle JH; DILIN Investigators.

Aliment Pharmacol Ther. 2019 May;49(9):1195-1204. doi: 10.1111/apt.15211. Epub 2019 Apr 1.

PMID:
30934130
23.

Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.

Corey KE, Wilson LA, Altinbas A, Yates KP, Kleiner DE, Chung RT, Krauss RM, Chalasani N; NASH Clinical Research Network.

Aliment Pharmacol Ther. 2019 May;49(9):1205-1213. doi: 10.1111/apt.15216. Epub 2019 Mar 10.

PMID:
30854694
24.

APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.

Roper N, Gao S, Maity TK, Banday AR, Zhang X, Venugopalan A, Cultraro CM, Patidar R, Sindiri S, Brown AL, Goncearenco A, Panchenko AR, Biswas R, Thomas A, Rajan A, Carter CA, Kleiner DE, Hewitt SM, Khan J, Prokunina-Olsson L, Guha U.

Cell Rep. 2019 Mar 5;26(10):2651-2666.e6. doi: 10.1016/j.celrep.2019.02.028.

25.

The Spectrum of Hepatic Involvement in Patients With Telomere Disease.

Kapuria D, Ben-Yakov G, Ortolano R, Cho MH, Kalchiem-Dekel O, Takyar V, Lingala S, Gara N, Tana M, Kim YJ, Kleiner DE, Young NS, Townsley DM, Koh C, Heller T.

Hepatology. 2019 Jun;69(6):2579-2585. doi: 10.1002/hep.30578. Epub 2019 Apr 10.

PMID:
30791107
26.

Tandem Orthotopic Living Donor Liver Transplantation Followed by Same Donor Haploidentical Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency.

Freeman AF, Yazigi N, Shah NN, Kleiner DE, Parta M, Atkinson P, Heller T, Holland SM, Kaufman SS, Khan KM, Hickstein DD.

Transplantation. 2019 Oct;103(10):2144-2149. doi: 10.1097/TP.0000000000002649.

PMID:
30720689
27.

The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection.

Townsend EC, Zhang GY, Ali R, Firke M, Moon MS, Han MAT, Fram B, Glenn JS, Kleiner DE, Koh C, Heller T.

J Gastroenterol Hepatol. 2019 Apr;34(4):764-775. doi: 10.1111/jgh.14617. Epub 2019 Feb 25.

PMID:
30695096
28.

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.

Agdashian D, ElGindi M, Xie C, Sandhu M, Pratt D, Kleiner DE, Figg WD, Rytlewski JA, Sanders C, Yusko EC, Wood B, Venzon D, Brar G, Duffy AG, Greten TF, Korangy F.

Cancer Immunol Immunother. 2019 Apr;68(4):599-608. doi: 10.1007/s00262-019-02299-8. Epub 2019 Jan 28.

29.

Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer.

Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, Krishnasamy V, Khan J, Wei JS, Agdashian D, Tyagi M, Gangalapudi V, Fioravanti S, Walker M, Anderson V, Venzon D, Figg WD, Sandhu M, Kleiner DE, Morelli MP, Floudas CS, Brar G, Steinberg SM, Korangy F, Greten TF.

Hepatology. 2019 May;69(5):2048-2060. doi: 10.1002/hep.30482. Epub 2019 Mar 10.

PMID:
30578687
30.

Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.

Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA; Nonalcoholic Steatohepatitis Clinical Research Network.

Hepatology. 2019 Aug;70(2):522-531. doi: 10.1002/hep.30418. Epub 2019 Mar 7.

PMID:
30549292
31.

FGF21 underlies a hormetic response to metabolic stress in methylmalonic acidemia.

Manoli I, Sysol JR, Epping MW, Li L, Wang C, Sloan JL, Pass A, Gagné J, Ktena YP, Li L, Trivedi NS, Ouattara B, Zerfas PM, Hoffmann V, Abu-Asab M, Tsokos MG, Kleiner DE, Garone C, Cusmano-Ozog K, Enns GM, Vernon HJ, Andersson HC, Grunewald S, Elkahloun AG, Girard CL, Schnermann J, DiMauro S, Andres-Mateos E, Vandenberghe LH, Chandler RJ, Venditti CP.

JCI Insight. 2018 Dec 6;3(23). pii: 124351. doi: 10.1172/jci.insight.124351.

32.

Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure.

Chen Z, Diaz G, Pollicino T, Zhao H, Engle RE, Schuck P, Shen CH, Zamboni F, Long Z, Kabat J, De Battista D, Bock KW, Moore IN, Wollenberg K, Soto C, Govindarajan S, Kwong PD, Kleiner DE, Purcell RH, Farci P.

Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11369-E11378. doi: 10.1073/pnas.1809028115. Epub 2018 Nov 12.

33.

17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.

Ma Y, Belyaeva OV, Brown PM, Fujita K, Valles K, Karki S, de Boer YS, Koh C, Chen Y, Du X, Handelman SK, Chen V, Speliotes EK, Nestlerode C, Thomas E, Kleiner DE, Zmuda JM, Sanyal AJ; (for the Nonalcoholic Steatohepatitis Clinical Research Network), Kedishvili NY, Liang TJ, Rotman Y.

Hepatology. 2019 Apr;69(4):1504-1519. doi: 10.1002/hep.30350. Epub 2019 Mar 5.

PMID:
30415504
34.

Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study.

Sterling RK, Wahed AS, King WC, Kleiner DE, Khalili M, Sulkowski M, Chung RT, Jain MK, Lisker-Melman M, Wong DK, Ghany MG; HIV-HBV Cohort Study of the Hepatitis B Research Network.

Am J Gastroenterol. 2019 May;114(5):746-757. doi: 10.1038/s41395-018-0409-9.

PMID:
30410040
35.

Microvascular inflammation in renal allograft biopsies assessed by endothelial and leukocyte co-immunostain: a retrospective study on reproducibility and clinical/prognostic correlates.

Delsante M, Maggiore U, Levi J, Kleiner DE, Jackson AM, Arend LJ, Hewitt SM, Carter-Monroe N, Bagnasco SM, Rosenberg AZ.

Transpl Int. 2019 Mar;32(3):300-312. doi: 10.1111/tri.13371. Epub 2018 Dec 11.

PMID:
30395360
36.

Expanding the phenotype of COPA syndrome: a kindred with typical and atypical features.

Taveira-DaSilva AM, Markello TC, Kleiner DE, Jones AM, Groden C, Macnamara E, Yokoyama T, Gahl WA, Gochuico BR, Moss J.

J Med Genet. 2018 Nov 1. pii: jmedgenet-2018-105560. doi: 10.1136/jmedgenet-2018-105560. [Epub ahead of print]

37.

Clinical and Histopathologic Features of Interstitial Lung Disease in Erdheim⁻Chester Disease.

Haroutunian SG, O'Brien KJ, Estrada-Veras JI, Yao J, Boyd LC, Mathur K, Gahl WA, Mirmomen SM, Malayeri AA, Kleiner DE, Jaffe ES, Gochuico BR.

J Clin Med. 2018 Aug 28;7(9). pii: E243. doi: 10.3390/jcm7090243.

38.

Spleen and Liver Volumetrics as Surrogate Markers of Hepatic Venous Pressure Gradient in Patients With Noncirrhotic Portal Hypertension.

Etzion O, Takyar V, Novack V, Gharib AM, Canales R, Adebogun A, Matsumoto E, Eccleston JL, Kleiner DE, Rosenzweig SD, Gunay-Aygun M, Uzel G, Fuss I, Childs R, Holland SM, Levy EB, Liang TJ, Heller T, Koh C.

Hepatol Commun. 2018 Jul 16;2(8):919-928. doi: 10.1002/hep4.1198. eCollection 2018 Aug.

39.

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab.

Suffredini DA, Lee JM, Peer CJ, Pratt D, Kleiner DE, Elinoff JM, Solomon MA.

BMC Pulm Med. 2018 Jul 11;18(1):112. doi: 10.1186/s12890-018-0681-x.

40.

Sclerosing Cholangitis-Like Changes on Magnetic Resonance Cholangiography in Patients With Drug Induced Liver Injury.

Ahmad J, Rossi S, Rodgers SK, Ghabril M, Fontana RJ, Stolz A, Hayashi PH, Barnhart H, Kleiner DE, Bjornsson ES.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):789-790. doi: 10.1016/j.cgh.2018.06.035. Epub 2018 Jun 30.

PMID:
29966706
41.

Molecular Signature and Mechanisms of Hepatitis D Virus-Associated Hepatocellular Carcinoma.

Diaz G, Engle RE, Tice A, Melis M, Montenegro S, Rodriguez-Canales J, Hanson J, Emmert-Buck MR, Bock KW, Moore IN, Zamboni F, Govindarajan S, Kleiner DE, Farci P.

Mol Cancer Res. 2018 Sep;16(9):1406-1419. doi: 10.1158/1541-7786.MCR-18-0012. Epub 2018 Jun 1.

42.

Recent Advances in the Histopathology of Drug-Induced Liver Injury.

Kleiner DE.

Surg Pathol Clin. 2018 Jun;11(2):297-311. doi: 10.1016/j.path.2018.02.009. Review.

43.

Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.

Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Brandman D, Doo E, Tonascia JA, Kleiner DE, Chalasani N, Sanyal AJ; NASH Clinical Research Network.

Clin Gastroenterol Hepatol. 2019 Jan;17(1):156-163.e2. doi: 10.1016/j.cgh.2018.04.043. Epub 2018 Apr 26.

44.

The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice.

Almeida LEF, Damsker JM, Albani S, Afsar N, Kamimura S, Pratt D, Kleiner DE, Quezado M, Gordish-Dressman H, Quezado ZMN.

Sci Rep. 2018 Apr 17;8(1):6081. doi: 10.1038/s41598-018-24274-6.

45.

Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B.

Khalili M, Shuhart MC, Lombardero M, Feld JJ, Kleiner DE, Chung RT, Terrault NA, Lisker-Melman M, Sanyal A, Lok AS; Hepatitis B Research Network (HBRN); Harvard Consortium.

Diabetes Care. 2018 Jun;41(6):1251-1259. doi: 10.2337/dc18-0040. Epub 2018 Mar 29.

46.

Mounier-Kuhn Syndrome Mimicking Lymphangioleiomyomatosis.

Pacheco GG, Jones AM, Yao J, Kleiner DE, Taveira-DaSilva AM, Moss J.

Chest. 2018 Feb;153(2):e19-e23. doi: 10.1016/j.chest.2017.10.024.

47.

Hepatocellular carcinoma: Liver biopsy in the balance.

Kleiner DE.

Hepatology. 2018 Jul;68(1):13-15. doi: 10.1002/hep.29831. No abstract available.

48.

Three variants in the nicotinamide adenine dinucleotide phosphate oxidase complex are associated with HCV-related liver damage.

Page SJ, Rivera MM, Kleiner DE, Zhao X, Auh S, Remmers EF, Heller T.

Hepatol Commun. 2017 Oct 23;1(9):973-982. doi: 10.1002/hep4.1103. eCollection 2017 Nov.

49.

Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.

Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H.

Hepatol Commun. 2017 May 19;1(4):288-292. doi: 10.1002/hep4.1043. eCollection 2017 Jun.

50.

Liver disturbances in activated phosphoinositide 3-kinase δ syndrome.

Ben-Yakov G, Kapuria D, Marko J, Cho MH, Pittaluga S, Kleiner DE, Koh C, Holland S, Uzel G, Heller T.

J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1763-1765. doi: 10.1016/j.jaip.2018.01.005. Epub 2018 Feb 16. No abstract available.

PMID:
29378322

Supplemental Content

Loading ...
Support Center